Diabetes treatment is constantly progressing, with new therapeutic options appearing to improve patient outcomes. Recent research have focused on GLP-1 and GIP receptor agonists, a category of drugs that mimic the actions of naturally occurring hormones involved in bloodlevel regulation. These novel agents demonstrate significant results in control

Retaglutide and tirzepatide represent cutting-edge class of medications known as dual GLP-1 and GIP agonists. These agents target both glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), two hormones that have a crucial role in regulating blood sugar levels. In individuals with type 2 diabetes, these hormones are